This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy
BMC Cancer Open Access 29 December 2018
-
Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib
Clinical Sarcoma Research Open Access 13 May 2013
-
Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease
Journal of Experimental & Clinical Cancer Research Open Access 07 October 2009
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Manley PW, Cowan-Jacob SW, Mestan J . Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta 2005; 1754: 3–13.
Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD . AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006; 94: 1765–1769.
Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354: 2006–2013.
Taylor JR, Brownlow N, Domin J, Dibb NJ . FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Oncogene 2006; 25: 147–151.
Roussel MF, Dull TJ, Rettenmier CW, Ralph P, Ullrich A, Sherr CJ . Transforming potential of the c-fms proto-oncogene (CSF-1 receptor). Nature 1987; 325: 549–552.
Morley GM, Uden M, Gullick WJ, Dibb NJ . Cell specific transformation by c-fms activating loop mutations is attributable to constitutive receptor degradation. Oncogene 1999; 18: 3076–3084.
Ando W, Hashimoto J, Nampei A, Tsuboi H, Tateishi K, Ono T et al. Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). J Bone Miner Metab 2006; 24: 274–282.
El Hajj Dib I, Gallet M, Mentaverri R, Sevenet N, Brazier M, Kamel S . Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. Eur J Pharmacol 2006; 551: 27–33.
Schubert C, Schalk-Hihi C, Struble GT, Ma HC, Petrounia IP, Brandt B et al. Crystal structure of the tyrosine kinase domain of colony-stimulating factor-1 receptor (cFMS) in complex with two inhibitors. J Biol Chem 2006; 282: 4094–4101.
Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 2004; 279: 31655–31663.
Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129–141.
Dewar AL, Domaschenz RM, Doherty KV, Hughes TP, Lyons AB . Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. Leukemia 2003; 17: 1713–1721.
Conway JG, McDonald B, Parham J, Keith B, Rusnak DW, Shaw E et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci USA 2005; 102: 16078–16083.
Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20: 757–766.
Dewar AL, Farrugia AN, Condina MR, Bik To L, Hughes TP, Vernon-Roberts B et al. Imatinib as a potential antiresorptive therapy for bone disease. Blood 2006; 107: 4334–4337.
Ohno H, Kubo K, Murooka H, Kobayashi Y, Nishitoba T, Shibuya M et al. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther 2006; 5: 2634–2643.
Pollard JW . Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71–78.
Irvine KM, Burns CJ, Wilks AF, Su S, Hume DA, Sweet MJ . A CSF-1 receptor kinase inhibitor targets effector functions and inhibits pro-inflammatory cytokine production from murine macrophage populations. FASEB J 2006; 20: 1921–1923.
Mundy GR . Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584–593.
Acknowledgements
We thank Jan Domin for advice and Stephen Marley, Myrtle Gordon, Ming Hu and Tasios Karadimitris for help with the osteoclast assays. We are also grateful to Malcolm Parker, Robert Winston and the IOG Trust for consumable contributions. NB and AR are recipients of BBSRC studentships.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Rights and permissions
About this article
Cite this article
Brownlow, N., Russell, A., Saravanapavan, H. et al. Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis. Leukemia 22, 649–652 (2008). https://doi.org/10.1038/sj.leu.2404944
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404944
This article is cited by
-
Tenosynovial giant cell tumor of the cervical spine: a case report
Spinal Cord Series and Cases (2019)
-
Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy
BMC Cancer (2018)
-
Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis
Current Treatment Options in Oncology (2016)
-
Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib
Clinical Sarcoma Research (2013)
-
Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro
Journal of Bone and Mineral Metabolism (2012)